Is Sotoracib (AMG510) available in China?

Sotorasib (AMG510, Sotorasib) has not yet been formally approved by the drug regulatory authorities in China, so it has not yet been marketed in mainland China. However, it is worth noting that sotoracib is already sold in Hong Kong, China, and patients can purchase it through formal channels. Sotorasib is available in tablet form, containing 120 mg of Sotorasib.

Sotorasiib is a prescription drug used to treat adult patients with non-small cell lung cancer (NSCLC): those who have spread to other parts of the body or cannot be removed by surgery, whose tumors have an abnormal KRAS G12C gene, and who have received at least one previous systemic treatment for the cancer (second-line treatment).

Sotoraxib is not a chemotherapy, immunotherapy, or tyrosine kinase inhibitor. This is an oral inhibitor designed specifically for patients with KRAS G12 mutations. 13% of patients with non-small cell lung cancer have an abnormal KRAS G12C gene. KRAS is an oncogene, a mutated (altered) form of a gene involved in normal cell growth. It produces mutated forms of the KRAS protein, which drives the development of lung and other cancers. Sotorasib contains the active ingredient sotorasib, which is designed to inactivate the mutant protein. Thereby blocking tumor growth and slowing down the disease.

Although it is not yet available in mainland China, patients still have the opportunity to obtain the drug through other means, such as traveling to Hong Kong to purchase it or participating in clinical trials. For patients who want to buy sotorasibu, it is recommended to consult a doctor first to understand whether their condition is suitable for using this drug, and to follow the doctor's advice and guidance. When purchasing, patients should choose regular and qualified medical institutions or pharmacies to ensure the authenticity and quality of the drugs.